Subtype
Malignant Pharyngeal Neoplasm
CI-CAN-00003219Explore in graph →
411 active trials1 approved drugs2 evidence items
- NCIt
- C7545
Loading cancer entity…
Subtype
CI-CAN-00003219Explore in graph →
Clinical trials
1,255 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (112)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05388773 | Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer | recruiting | Phase 2 | 150 | Heath SkinnerOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04852328 | Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma | recruiting | Phase 2 | 30 | Washington University School of MedicineOTHER | 1 | Jul 20, 2026 |
| clinicaltrials |
| NCT06662058 | Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation | recruiting | N/A | 118 | Emory UniversityOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07665190 | Neoadjuvant EGFR-ADC Combined With Anti-PD-1 Monoclonal Antibody in Resectable Locally Advanced Hypopharyngeal Squamous Cell Carcinoma(RESERVE-HC) | recruiting | Phase 2 | 52 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07706985 | Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal Carcinoma | recruiting | Phase 3 | 566 | Sun Yat-sen UniversityOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT01365169 | Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients" | recruiting | N/A | 590 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT05799144 | pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer | recruiting | Phase 2 | 54 | Michael K. GibsonOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07705243 | Efficacy and Safety of Becotatug Vedotin (MRG003) Combined With Anti-PD1 as Maintenance Therapy for Recurrent and Metastatic Nasopharyngeal Carcinoma | recruiting | Phase 3 | 86 | Sun Yat-sen UniversityOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT05451004 | SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer(SELECT) | recruiting | Phase 3 | 510 | Canadian Cancer Trials GroupNETWORK | 2 | Jul 14, 2026 | clinicaltrials |
| NCT06797986 | A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC. | recruiting | Phase 1 / Phase 2 | 37 | Cellid Co., Ltd.INDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06788002 | LDRT and Chemoimmunotherapy in NPC With Liver Metastasis(Light) | recruiting | Phase 2 | 26 | Hunan Cancer HospitalOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07686575 | Objective Response Rate of Ivonescimab With Chemotherapy in Locally Advanced Resectable Oral and Oropharyngeal Squamous Cell Carcinoma | recruiting | — | 20 | Zhujiang HospitalOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT05522881 | The Registry Study of Genetic Alterations of Oropharyngeal Cancer in Taiwan | recruiting | — | 410 | National Health Research Institutes, TaiwanOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT02012699 | Integrated Cancer Repository for Cancer Research(iCaRe2) | recruiting | — | 999,999 | University of NebraskaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT04151082 | High Dose Steroid Therapy (Prednisone or Methylprednisolone) for the Improvement of Symptoms of Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer Survivors | recruiting | Phase 1 / Phase 2 | 35 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT06592599 | Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC) | recruiting | Phase 2 | 24 | Stanford UniversityOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT06682442 | Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma | recruiting | N/A | 66 | University of California, San FranciscoOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT05639972 | E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers | recruiting | Phase 1 / Phase 2 | 15 | Christian HinrichsOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05686226 | E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | recruiting | Phase 2 | 20 | Christian HinrichsOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06821243 | Patients With Human Papillomavirus-associated Head and Neck Cancer for the Discovery of Predictive Biomarkers to Guide Clinical Intervention | recruiting | — | 40 | Regina Elena Cancer InstituteOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07590024 | RAIRI Model-Guided Adjuvant Therapy in Nasopharyngeal Carcinoma(RAIRI-NPC) | recruiting | Phase 3 | 651 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07618078 | Real-World RAIRI-Guided Risk Stratification for Adjuvant Therapy Benefit After Chemoradiotherapy in NPC | recruiting | — | 900 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT06851663 | Trop2-targeted immunoPET Imaging of Solid Tumors | recruiting | Phase 2 / Phase 3 | 400 | RenJi HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT05910827 | A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers | recruiting | Phase 1 / Phase 2 | 398 | Hummingbird BioscienceINDUSTRY | 5 | May 27, 2026 | clinicaltrials |
| NCT05800574 | Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer | recruiting | Phase 2 | 22 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07325539 | LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC(LIGHT) | recruiting | Phase 2 | 55 | Sun Yat-sen UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07497607 | Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma(REDUCE-30) | recruiting | Phase 2 | 31 | Sara MedekOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT06277050 | Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma | recruiting | Phase 3 | 264 | Jiangxi Provincial Cancer HospitalOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07584499 | Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors(MRG003) | recruiting | Phase 1 | 51 | Sun Yat-sen UniversityOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT05541016 | De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA | recruiting | Phase 2 | 455 | Mayo ClinicOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT06747390 | Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery(856397) | recruiting | Phase 1 | 30 | Ryan CareyOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT06852638 | CD70-targeted immunoPET Imaging of Malignant Cancers | recruiting | Phase 2 | 300 | RenJi HospitalOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07581821 | Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma | recruiting | Phase 2 | 33 | Ming-Yuan ChenOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT04436965 | Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition | recruiting | Phase 3 | 266 | Sun Yat-sen UniversityOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05340491 | Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial | recruiting | Phase 3 | 212 | Sun Yat-sen UniversityOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05941741 | IC Plus Low-dose Radiation Plus Cadonilimab in LANPC | recruiting | Phase 3 | 380 | Sun Yat-sen UniversityOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT06197776 | Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC | recruiting | — | 50 | Sun Yat-sen UniversityOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT06323239 | SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma | recruiting | Phase 2 | 148 | Sun Yat-sen UniversityOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT06802835 | EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma | recruiting | Phase 1 / Phase 2 | 148 | Sun Yat-sen UniversityOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT06984861 | A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer | recruiting | Phase 2 | 74 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT06997068 | Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population | recruiting | Phase 2 | 25 | Mayo ClinicOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT04425265 | Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma | recruiting | N/A | 500 | Sun Yat-sen UniversityOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06682494 | Enhancing Oral Cancer Awareness | recruiting | N/A | 60 | Virginia Commonwealth UniversityOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT03907826 | PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients | recruiting | Phase 3 | 212 | Sun Yat-sen UniversityOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT07311772 | Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid | recruiting | Phase 3 | 386 | Sun Yat-sen UniversityOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT05600842 | De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx | recruiting | — | 111 | University of California, IrvineOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07013461 | International Collaborative Study on AJCC/UICC TNM-10 for Nasopharyngeal Cancer | recruiting | — | 5,000 | The University of Hong Kong-Shenzhen HospitalOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT04944914 | Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma | recruiting | Phase 3 | 188 | Sun Yat-sen UniversityOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT04564989 | Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC | recruiting | — | 220 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05268614 | Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma | recruiting | Phase 2 | 250 | University of FloridaOTHER | 1 | Apr 24, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 21, 2026source: clinicaltrials